Africa’s Silent Pandemic: Antimicrobial Resistance Is Killing More People Than HIV and Malaria Combined
While the world’s attention remains fixed on emerging infectious disease threats, a quieter — and in many ways deadlier — crisis has taken root across the African continent. Antimicrobial resistance (AMR), the process by which bacteria, viruses, fungi, and parasites evolve to defeat the drugs designed to kill them, is now responsible for more deaths in Africa annually than HIV/AIDS and malaria combined. And unlike a novel virus outbreak, AMR is a slow-burning emergency that receives a fraction of the global health funding and political attention it demands.
A landmark study published in The Lancet in 2025 estimated that AMR accounted for 1.27 million deaths globally in a single year, with sub-Saharan Africa bearing a disproportionate burden. In many African nations, common infections that were once routinely treatable — urinary tract infections, surgical wounds, pneumonia — are becoming lethal as first-line antibiotics fail.
A Crisis Decades in the Making
The roots of Africa’s AMR crisis are complex and deeply intertwined with the region’s broader development challenges. Overuse and misuse of antimicrobials in human medicine is the primary driver, but in many African countries, the problem is compounded by a lack of regulatory oversight that allows antibiotics to be sold over-the-counter without prescriptions. In villages and markets across Nigeria, Kenya, Ghana, and the Democratic Republic of Congo, individuals routinely purchase antibiotics for conditions as minor as a cold — a viral infection against which antibiotics have zero effect.
In the agricultural sector, the picture is equally alarming. Antimicrobials are widely used in livestock farming as growth promoters and prophylactic agents, a practice that is banned in many developed countries but remains common across Africa’s rapidly expanding meat and fish farming industries. The result is a vast reservoir of resistant bacteria in animals that can be transmitted to humans through the food chain, through contaminated water, and through direct contact.
The Human Cost in Tangible Terms
For families across Africa, AMR transforms routine medical procedures into life-threatening gambles. In Kenya’s public hospitals, surgeons report a growing incidence of post-operative infections that do not respond to standard antibiotic protocols. In Ghana, neonatal units have recorded rising rates of sepsis caused by multidrug-resistant organisms — infections that, in a functioning healthcare system with access to second and third-line antibiotics, would be manageable.
Dr. Amara Diallo, a pediatric infectious disease specialist at a major teaching hospital in Dakar, Senegal, describes the reality on the ground: "We are seeing bacteria that we simply cannot treat with the drugs we have available. We are back to the pre-antibiotic era for some patients. We watch them die because we have nothing effective left to give them."
A Path Forward: What Africa Must Do — and Fast
Addressing AMR in Africa requires action across multiple fronts simultaneously. The World Health Organization’s Global Action Plan on AMR, to which all African Union member states have committed, provides a framework, but implementation remains patchy, underfunded, and inconsistent.
The most urgent priorities are clear to experts. First, and most fundamentally, there must be a dramatic reduction in the unnecessary use of antimicrobials in both human and animal health. This requires public awareness campaigns, stronger regulatory enforcement, and training programmes for healthcare workers and veterinarians alike.
Second, laboratory capacity must be dramatically expanded. In many African countries, bacterial infections are diagnosed clinically — based on symptoms alone — without the microbiological testing that would allow clinicians to identify which drugs a pathogen is resistant to.
Third, surveillance networks must be built and maintained. Africa’s contribution to global AMR surveillance data is woefully incomplete, meaning the true scale of the crisis remains partially invisible to policymakers and donors.
Fourth, investment in new antibiotic development must be accompanied by investment in access. The pipeline for new antibiotics is fragile globally, with few pharmaceutical companies maintaining active research programmes in the field.
A Race Against Time
The clock is ticking. Antimicrobial resistance does not make headlines the way a novel disease outbreak does, but it is killing people every day — in hospitals, in communities, and in homes across Africa. Without urgent, coordinated action, the continent risks sliding back into an era in which minor infections are once again death sentences.
Image: WHO / IHME Global Burden of Disease Study